Quantification of maternal serum cell-free fetal DNA in early-onset preeclampsia

International Journal of Molecular Sciences

Volumn 14, Issue 4, 2013, Pages 7571-7582

  Yu, Hong ^a   Shen, Yanting ^a   Ge, Qinyu ^a   He, Youji ^a   Qiao, Dongyan ^a   Ren, Mulan ^a   Zhang, Jianqiong ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Cell free fetal DNA; HCG; Preeclampsia

Indexed keywords

ALPHA FETOPROTEIN; CELL DNA; CELL FREE FETAL DNA; CHORIONIC GONADOTROPIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DNA;

ABORTION; ADULT; ARTICLE; BIRTH WEIGHT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; EARLY ONSET PREECLAMPSIA; FAMILY HISTORY; FEMALE; GESTATIONAL AGE; GONADOTROPIN BLOOD LEVEL; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; MATERNAL AGE; MATERNAL SERUM; MEDICAL HISTORY; NEPHRITIS; PREECLAMPSIA; PRENATAL SCREENING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; CLINICAL TRIAL; FETUS; MALE; PREGNANCY; PREGNANCY OUTCOME; Y CHROMOSOME;

ADULT; BIOLOGICAL MARKERS; CHROMOSOMES, HUMAN, Y; DNA; FEMALE; FETUS; HUMANS; MALE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; SENSITIVITY AND SPECIFICITY;

EID: 84876002574     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14047571     Document Type: Article

References (36)

1. Hahn, S.; Rusterholz, C.; Hosli, I.; Lapaire, O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta 2011, 32, S17-S20.
2. Redman, C.W.; Sargent, I.L. Placental stress and preeclampsia: A revised view. Placenta 2009, 30, S38-S42.
3. Sibai, B.M.; Barton, J.R. Expectant management of severe preeclampsia remote from term: Patient selection, treatment, and delivery indications. Am. J. Obstet. Gynecol. 2007, 196, 514. e1-9.
4. Lo, Y.M.; Corbetta, N.; Chamberlain, P.F.; Rai, V.; Sargent, I.L.; Redman, C.W.; Wainscoat, J.S. Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350, 485-487.
5. Hyett, J.A.; Gardener, G.;Stojilkovic-Mikic, T.; Finning, K.M.; Martin, P.G.; Rodeck, C.H.; Chitty, L.S. Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy. Prenat. Diagn. 2005, 25, 1111-1116.
6. Finning, K.; Martin, P.; Daniels, G. A clinical service in the UK to predict fetal Rh(Rhesus) D blood group using free fetal DNA in maternal plasma. Ann. N. Y. Acad. Sci. 2004, 1022, 119-123.
7. Daniels, G.; Finning, K.; Martin, P.; Massey, E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: Current practice and future prospects. Prenat. Diagn. 2009, 29, 101-107.
8. Zhao, F.; Wang, J.; Liu, R.;Yang, J.; Cui, K.; Wu, Y.; Guo, J.; Mu, Y.; Wang X. Quantification and application of the placental epigenetic signature of the RASSF1A gene in maternal plasma. Prenat. Diagn. 2010, 30, 778-782.
9. Sifakis, S.; Zaravinos, A.; Maiz, N.; Spandidos, D.A.; Nicolaides, K.H. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am. J. Obstet. Gynecol. 2009, 201, 472. e1-7.
10. Lo, Y.M.; Leung, T.N.; Tein, M.S.; Sargent, I.L.; Zhang, J.; Lau, T.K.; Haines, C.J.; Redman, C.W. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin. Chem. 1999, 45, 184-188.
11. Zhong, X.Y.; Laivuori, H.; Livingston, J.C.; Ylikorkala, O.; Sibai, B.M.; Holzqreve, W.; Hahn, S. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am. J. Obstet. Gynecol. 2001, 184, 414-419.
12. Smid, M.; Vassallo, A.; Lagona, F.; Valsecchi, L.; Maniscalco, L.; Danti, L.; Lojacono, A.; Ferrar, A.; Ferrari, M.; Cremonesi, L. Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities. Ann. N. Y. Acad. Sci. 2001, 945, 132-137.
13. Swinkels, D.W.; de Kok, J.B.; Hendriks, J.C.; Wiegerinck, E.; Zusterzeel, P.L.; Steegers, E.A. Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA inmaternal plasma and serum. Clin. Chem. 2002, 48, 650-653.
14. Lau, T.W.; Leung, T.N.; Chan, L.Y.; Lau, T.K.; Chan, K.C.; Tam, W.H.; Lo, YM. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin. Chem. 2002, 48, 2141-2146.
15. Sekizawa, A.; Jimbo, M.; Saito, H.; Iwasaki, M.; Matsuoka, R.; Okai, T.; Farina, A. Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. Am. J. Obstet. Gynecol. 2003, 188, 480-484.
16. Shimada, K.; Murakami, K.; Shozu, M.; Segawa, T.; Sumitani, H.; Inoue, M. Sex-determining region Y levels in maternal plasma: Evaluation in abnormal pregnancy. J. Obstet. Gynaecol. Res. 2004, 30, 148-154.
17. Farina, A.; Sekizawa, A.; Rizzo, N.; Concu, M.; Banzola, I.; Carinci, P.; Simonazzi, G.; Okai, T. Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. Prenat. Diagn. 2004, 24, 293-297.
18. Zhong, X.Y.; Gebhardt, S.; Hillermann, R.; Tofa, K.C.; Holzgreve, W.; Hahn, S. Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early-and late-onset preeclampsia. Clin. Chem. 2005, 51, 1730-1733.
19. Smid, M.; Galbiati, S.; Lojacono, A.; Valsecchi, L.; Platto, C.; Cavoretto, P.; Calza, S.; Ferrari, A.; Ferrari M.; Cremonesi, L. Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies. Prenat. Diagn. 2006, 26,785-790.
20. Leung, T.N.; Zhang, J.; Lau, T.K.; Lo, Y.M. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin. Chem. 2001, 47, 137-139.
21. Zhong, X.Y.; Holzgreve, W.; Hahn, S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens. Pregnancy 2002, 21, 77-83.
22. Levine, R.J.; Qian, C.; Leshane, E.S.; Yu, K.F.; Enqland, L.J.; Schisterman, E.F.; Wataqanara, T.; Romero, R.; Bianchi, D.W. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am. J. Obstet. Gynecol. 2004, 190, 707-713.
23. Farina, A.; Sekizawa, A.; Sugito, Y.; Iwasaki, M.; Jimbo, M.; Saito, H.; Okai, T. Fetal DNA in maternal plasma as a screening variable for preeclampsia: A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenat. Diagn. 2004, 24, 83-86.
24. Crowley, A.; Martin, C.; Fitzpatrick, P.; Sheils, O.; O'Herlihy, C.; O'Leary, J.J.; Byrne, B.M. Free fetal DNA is not increased before 22 weeks in intrauterine growth restriction or preeclampsia. Prenat. Diagn. 2007, 27, 174-179.
25. Lazar, L.; Rigó, J., Jr.; Nagy, B.; Balogh, K.; Makó, V.; Cervenak, L.; Mézes. M.; Prohászka, Z.; Molvarec, A. Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia. BMC Med. Genet. 2009, 10, doi:10.1186/1471-2350-10-120.
26. Morris, R.K.; Cnossen, J.S.; Langejans, M.; Robson, S.C.; Kleijnen, J.; TerRiet, G.; Mol, B.W.; van der Post, J.A.; Khan, K.S. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: Systematic review and meta-analysis. BMC Pregnancy Childbirth 2008, 8, doi:10.1186/1471-2393-8-33.
27. Di LorenzoDi Lorenzo, G.; Ceccarello, M.; Cecotti, V.; Ronfani, L.; Monasta, L.; Vecchi Brumatti, L.; Montico, M.; D'Ottavio, G. First trimester maternal serum PIGF, free b-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. Placenta 2012, 33, 495-501.
28. Audibert, F.; Boucoiran, I.; An, N.; Aleksandrov, N.; Delvin, E.; Bujold, E.; Rey, E. Screening for preeclampsia using first-trimester serummarkers and uterine artery Doppler in nulliparous women. Am. J. Obstet. Gynecol. 2010, 203, 383. e1-8.
29. Tjoa, M.L.; Cindrova-Davies, T.; Spasic-Boskovic, O.; Bianchi, D.W.; Burton, G.J. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am. J. Pathol. 2006, 169, 400-404.
30. Ahn, H.; Park, J.; Gilman-Sachs, A.; Kwak-Kim, J. Immunologic characteristics of preeclampsia, a comprehensive review. Am. J. Reprod. Immunol. 2011, 65, 377-394.
31. Servitje, E.L.; Lopez, N.G.; Olson, D.M. An immunological insight into the origins of preeclampsia. Hum. Reprod. Update 2010, 16, 510-524.
32. Uzan, J.; Carbonnel, M.; Piconne, O.; Asmar, R.; Ayoubi, J.M. Pre-eclampsia: Pathophysiology, diagnosis, and management. Vasc. Health Risk Manag. 2011, 7, 467-474.
33. Chen, J.Z.; Sheehan, P.M.; Brennecke, S.P.; Keogh, R.J. Vessel remodelling, pregnancy hormones and extravilloustrophoblast function. Mol. Cell. Endocrinol. 2012, 349, 138-144.
34. Jin, H.K.; Antonio, F.; Ji, H.P. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: Correlation with the week of onset and the severity. Prenat. Diagn. 2008, 28, 704-709.
35. Lambert-Messerlian, G.M.; Silver, H.M.; Petraglia, F.; Luisi, S.; Pezzani, I.; Maybruck, W.M.; Hogge, W.A.; Hanley-Yanez, K.; Roberts, J.M.; Neveux, L.M.; et al. Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin a as predictiors of preeclampsia in the third trimester of pregnancy. J. Soc. Gynecol. Invest. 2000, 7, 170-174.
36. Davey, D.A.; MacGillivray, I. The classification and definition of the hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol. 1988, 158, 892-898.